IPO - PLUS THERAPEUTICS, INC.

Form Type: S-1

Filing Date: 2025-06-18

Corporate Action: Ipo

Type: New

Accession Number: 000119312525142215

Filing Summary: Plus Therapeutics, Inc. has filed a Form S-1 registration statement for the public offering of up to 17,000,000 shares of its common stock, par value $0.001 per share, which will be made available to Lincoln Park Capital Fund, LLC through a purchase agreement. The company will not be selling any securities in the offering and will not receive proceeds from the sale by Lincoln Park. However, they could receive up to $50 million in gross proceeds from the sales of common stock to Lincoln Park under the terms of the purchase agreement. The filing mentions that the current common stock outstanding totals 50,998,468 shares and, assuming the sale of all registered shares, it will increase to 67,998,468 shares post-offering. The agreement includes a commitment fee of $500,000 payable to Lincoln Park for their investment commitment, with additional fees contingent on future sales. The document emphasizes the potential risks involved with such investments and notes the importance of the 'Risk Factors' section for potential investors. Plus Therapeutics is focused on developing targeted therapy for central nervous system cancers using advanced radioactive drug formulations.